Kayentis, a global expert in eCOA, is strenghening its US presence
19 June 2018
Kayentis, expert in eCOA, is stengthening its presence in the US and opening offices in Boston. Guillaume Juge, Kayentis CEO explains the rationale for this expansion in the US.
Why is Kayentis opening new offices in Boston and expanding its staff?
Our company’s business development and competitive strategy includes the rapid growth of our presence in the United States.
The opening of our Boston office reinforces our customer-focused approach. To ensure high-quality support for clinical studies we want to remain close to our clients with a presence wherever it is needed, in Europe, Asia, and the US.
Why is now the time for this increased presence in the US?
We significantly increased our US footprint last year with projects with new clients including pharma, biotech, and CROs. This increase in activity will continue to grow over the coming year.
Furthermore, we’ve spent time to ensure effective links between our US and European operations, and now have everything in place to ensure a consistent and harmonized expansion in the US.
What is your development strategy in the US?
Our ambition is to become the 3rd largest eCOA player globally and the best in terms of quality of service.
To support our US development and activities, the US team will grow quickly in the coming months and years, as has been the case for our teams in Europe.
In parallel, we will continue to innovate and improve our eCOA solution, Clin’form3 Suite, to deliver best-in-class eCOA data capture solutions. We strive to provide customers, clinical sites, and patients the most efficient, easy-to-use, and comprehensive solutions. We aim to be a leading reference in innovation in eCOA market through the quality of our solutions, services, and databases that we provide to Sponsors and CROs.
We are committed to contributing to the reliability of clinical research, and to helping to improve human health.
Guillaume JUGE, CEO Kayentis